Heparin monitoring in sheep by activated partial thromboplastin time

Artificial Organs

Volumn 27, Issue 6, 2003, Pages 576-580

  Park, Seok Gon ^a   Kim, Seung Chul ^a,b   Choi, Min Joo ^a   Lee, Hyuk Soo ^c   Min, Byoung Goo ^d   Cheong, Jongtae ^a   Lee, Kyoungkap ^a  

^a Jeju National University   (South Korea)

^b Hanmaeum Hospital   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

Activated partial thromboplastin time; Heparin; Platelet count; Sheep

Indexed keywords

ANIMALS; ANTHROPOMETRY; POLYSACCHARIDES;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; AFTER-TREATMENT; ANTI-COAGULATION; BASELINE VALUES; BODY WEIGHT; PLATELET COUNT; SHEEP; THERAPEUTIC RANGE; TIME RATIO; VASCULAR SURGERY;

PLATELETS;

FIBRINOGEN; HEPARIN;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CARBOHYDRATE ANALYSIS; CELL ASSAY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG MECHANISM; FEMALE; HEPARINIZATION; MALE; MONITORING; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN DETERMINATION; SHEEP; THROMBOCYTE COUNT; TIME;

ANIMALIA; OVIS ARIES;

EID: 0038179381     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.2003.07090.x     Document Type: Article

References (27)

1. Wessler S, Gitel SN. Pharmacology of heparin and warfarin. J Am Coll Cardiol 986;8:10B-20B.
2. Christiansen S, Jahn UR, Meyer J, Scheld HH, Aken HV, Kehrel BE, Hammel D. Anticoagulative management of patients requiring left ventricular assist device implantation and suffering from heparin-induced thrombocytopenia type II. Ann Thorac Surg 2000;69:774-7.
3. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: heparin. Circulation 1994;89:1449-68.
4. Hirsh J. Drug therapy - Heparin. N Engl J Med 1991;324:1565-74.
5. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14.
6. Teoh KHT, Young E, Bradly CA, Hirsh J. Heparin binding proteins-Contribution to heparin rebound after cardiopulmonary bypass. Circulation 1993;88:420-5.
7. Zucker S, Cathey MH. Control of heparin therapy. Sensitivity of the activated partial thromboplastin time for monitoring the antithrombotic effect of heparin. J Lab Clin Med 1968;73:320-6.
8. Triplett DA, Harms CS, Koepke JA. The effect of heparin on the activated partial thromboplastin time. Am J Clin Pathol 1978;70:556-9.
9. Bain B, Forster T, Sleigh B. Heparin and activated partial thromboplastin time - A difference between the in-vitro and in-vivo effects and implications for therapeutic range. Am J Clin Pathol 1980;74:668-73.
10. Gravlee GP, Case LD, Angert KC, Rogers AT, Miller GS. Variability of the activated coagulation time. Anesth Analg 1988;67:469-72.
11. Simko RJ, Tsung FF, Stanek EJ. Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin. Ann Pharmacother 1995;29:1015-21.
12. Scialla SJ. Heparin monitoring by activated partial thromboplastin time. Am J Clin Pathol 1985;84:351-4.
13. Reiner JS, Coyne KS, Lundergan CF, Ross AM. Bedside monitoring of heparin therapy:comparision of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn 1994;32:49-52.
14. Cipolle RJ, Seifert RD, Neilan BA, Zaske DE, Haus E, Heparin kinetics: Variables related to disposition and dosage. Clin Pharmacol Ther 1981;29:387-93.
15. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992;67:639-43.
16. Olsson P, Lagergren H, Sk S. The elimination from plasma of intravenous heparin: An experimental study on dogs and humans. Acta Med Scand 1963;173:619-30.
17. De Swart CAM, Nijmeyer B, Roelofs JMM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982;60:1251-8.
18. Banez EI, Triplett DA, Koepke J. Laboratory monitoring of heparin therapy - The effect of different salt of heparin on the activated partial thromboplastin time. Am J Clin Pathol 1980;74:569-74.
19. Brill-Edward P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104-9.
20. Saya FG, Coleman LT, Martinoff JT. Pharmacist-directed heparin therapy using a standard dosing and monitoring protocol. Am J Hosp Pharm 1985;42:1965-9.
21. Carter BL. Therapy of acute thromboembolism with heparin and warfarin. Clin Pharm 1991;10:503-18.
22. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fraction on platelet aggregation. J Clin Invest 1980;65:64-73.
23. Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977;2:581-4.
24. Becker RC, Cyr J, Corrao JM, Ball SP. Bedside coagulation monitoring in heparin-treated patients with active thromboembolic disease: A coronary care unit experience. Am Heart J 1994;128:719-23.
25. Heras M, Chesebro JH, Penny WJ, Bailey KR, Lain JYT, Holmes DR, Reeder GS, Badimon L, Fuster V. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988;78:654-60.
26. Schiele A, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP. Use of recombinant hirudine as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995;50:20-5.
27. th ed. Ithaca: Comstock, Cornell University Press. 1993:40.